Adult Dosing
Acute migraine attacks (with or without aura)
- 4-6 mg SC x 1; may repeat dose after 1 hr if headache recurs
- MAX: 2 doses/24 hrs; 12 mg/24 hours
Cluster headache
- 4-6 mg SC x 1; may repeat dose after 1 hr if headache recurs
- MAX: 2 doses/24 hrs; 12 mg/24 hours
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
See Supplemental Patient Information
- For SC use only; give first dose in an adequate medical facility and obtain ECG after injection
- Sumatriptan should be given only if a clear diagnosis of migraine has been established
- Life-threatening and fatal hypersensitivity reactions (eg, anaphylaxis or anaphylactoid) have been reported
- Sumatriptan is not indicated for prophylaxis of migraine or for use in the management of hemiplegic or basilar migraine
- Serious adverse cardiac events, including acute MI, arrhythmias, and death, have occurred within a few hours following administration
- Do not give when risk factors for ischemic, cerebrovascular, or peripheral vascular syndromes are present. Unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors e.g. hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age. Do not use unless a cardiovascular evaluation establishes that the patient does not have CAD
- It may cause coronary vasospasm in patients with history of coronary artery disease (CAD)
- Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have occurred with 5-HT1 agonists
- Gastrointestinal ischemic events and peripheral vasospastic reactions (e.g. Raynaud’s syndrome) have been reported. Peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea have occurred
- Life-threatening serotonin syndrome may occur, particularly when combined with serotonin reuptake inhibitors
- Intermittent long term users should undergo periodic cardiovascular evaluation
- Monitor BP at baseline, cardiovascular evaluation at baseline, then periodically during long-term treatment if risk factors present
- Overuse of migraine drugs may lead to worsening of headache, or increase in frequency of migraine attacks. Consider detoxification process, including withdrawal of the overused drugs, and treatment for withdrawal symptoms in patients who overuse migraine drugs
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Diabetes Mellitus
- Hypertension (due to possibility of unrecognised CAD)
- Cardiac risk factors
- Hx of seizure disorder
- Geriatric population (due to presence of risk factors for hypertension, hypercholesterolemia, possibility of unrecognized CAD)
Supplemental Patient Information
- CV: Chest pain/pressure/tightness/heaviness, hypertension, palpitations, coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, ventricular fibrillation, arrhythmias, hypertensive crisis, flushing
- CNS: Dizziness, drowsiness, somnolence, insomnia, vertigo, cerebral hemorrhage, subarachnoid hemorrhage
- NEURO: Hyperesthesia, paresthesia, numbness
- EENT: Neck/jaw/throat pain/tightness/pressure, nasal irritation, throat discomfort, vision loss
- DERM: Burning sensation
- GI: Nausea/vomiting, abdominal pain, GI ischemic events, dysphagia, bad/unusual test
- LOCAL: Inj site reactions
- MUSC: Myalgias, myasthenia, neck pain, stiffness
- MISC: Hypersensitivity reactions, asthenia, sweating, feeling of heaviness, pain
Alsuma, Imitrex, Imitrex STATdose, Sumavel DosePro interacts with :
Pregnancy Category:C
Breastfeeding: Sumatriptan is excreted in breastmilk in low levels; it would not be expected to cause any adverse effects in breastfed infants. Withholding breastfeeding for 8 hrs after a single SC injection would virtually eliminate infant exposure. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT).This drug is considered compatible with breastfeeding based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776 last accessed 8 September 2009). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Imitrex STATdose Refill 6 MG/0.5ML SOLN [Syringe] (GLAXO SMITH KLINE)
1 0.5ml = $217.16
3 0.5ml = $603.25 - Imitrex STATdose System 6 MG/0.5ML SOLN [Cartridge] (GLAXO SMITH KLINE)
1 0.5ml = $217.16
3 0.5ml = $628.59 - Sumavel DosePro 6 MG/0.5ML DEVI [Syringe] (ZOGENIX)
0.5 0.5ml = $106.99
1.5 0.5ml = $304.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
